Immunovant Inc Net Income per Employee (IMVT), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Immunovant Inc   (NASDAQ: IMVT)
 

Immunovant Inc Net Income per Employee

IMVT's Quarterly Results, Trends, Rankings, Statistics
Immunovant Inc recorded a cumulative net loss of $-538 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 129 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 4052, from total ranking in previous quarter at 4598.


What is Income per Employee Ratio?






IMVT Net Income per Employee (Jun 30 2026)
I. Quarter
(Mar 31 2026)
IV. Quarter
(Dec 31 2025)
III. Quarter
(Sep 30 2025)
II. Quarter
(Jun 30 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,600,082 -2,442,541 -2,242,507 -2,244,860 -2,160,884
IMVT's Total Ranking # 4052 # 4598 # 4235 # 4340 # 4309
Seq. Net Income Change - - - - -


IMVT Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 130
Healthcare Sector # 817
Overall Market # 4052

Net Income per Employee Statistics
High Average Low
$ -2 $ -1,143,639 $ -2,600,082
  (Jun 30 2026)







Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-05T15:13:58+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.